Monitoring CAR T cells in peripheral blood by flow cytometry following Tisagenlecleucel in Fundeni Clinical Institute, Bucharest

1 Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019 May;94(S1):S3-9. DOI: 10.1002/ajh.25418 Search in Google Scholar

2 Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S, et al. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. N Engl J Med. 2021 Aug 5;385(6):567-9. DOI: 10.1056/NEJMc2107725 Search in Google Scholar

3 Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020 Mar;17(3):147-67. DOI: 10.1038/s41571-019-0297-y Search in Google Scholar

4 Jensen MC, Riddell SR. Designing chimeric antigen receptors to effectively and safely target tumors. Curr Opin Immunol. 2015 Apr;33:9-15. DOI: 10.1016/j.coi.2015.01.002 Search in Google Scholar

5 Fujiwara K, Tsunei A, Kusabuka H, Ogaki E, Tachibana M, Okada N. Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold. Cells. 2020 May 9;9(5):1182. DOI: 10.3390/cells9051182 Search in Google Scholar

6 Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014 Jan;257(1):107-26. DOI: 10.1111/imr.12131 Search in Google Scholar

7 Gerdemann U, Christin AS, Vera JF, Ramos CA, Fujita Y, Liu H, et al. Nucleofection of DCs to Generate Multivirus-specific T Cells for Prevention or Treatment of Viral Infections in the Immunocompromised Host. Mol Ther. 2009 Sep 1;17(9):1616-25. DOI: 10.1038/mt.2009.140 Search in Google Scholar

8 FDA approves axicabtagene ciloleucel for large B-cell lymphoma. FDA [Internet]. 2019 Feb 9 [cited 2023 Apr 19]; Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-axicabtagene-ciloleucel-large-b-cell-lymphoma Search in Google Scholar

9 FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome. FDA [Internet]. 2019 Feb 9 [cited 2023 Apr 19]; Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tisagenlecleucel-b-cell-all-and-tocilizumab-cytokine-release-syndrome Search in Google Scholar

10 Sadelain M, Rivière I, Riddell S. Therapeutic T cell engineering. Nature. 2017 May;545(7655):423-31. DOI: 10.1038/nature22395 Search in Google Scholar

11 Kawalekar OU, O’Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD, et al. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. Immunity. 2016 Feb 16;44(2):380-90. DOI: 10.1016/j. immuni.2016.01.021 Search in Google Scholar

12 Philipson BI, O’Connor RS, May MJ, June CH, Albelda SM, Milone MC. 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling. Sci Signal. 2020 Mar 31;13(625):eaay8248. DOI: 10.1126/scisignal.aay8248 Search in Google Scholar

13 Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020 Nov 10;4(21):5414-24. DOI: 10.1182/bloodadvances.2020003092 Search in Google Scholar

14 Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol. 2012 Feb 17;12(3):191-200. DOI: 10.1038/nri3158 Search in Google Scholar

15 Miltenyi Biotec. CD19 CAR Detection Reagent Protocol [Internet]. Available from: https://www.miltenyibiotec.com/upload/assets/IM0028385.PDF Search in Google Scholar

16 BD Biosciences. BD Biosciences TBNK Instructions For Use [Internet]. Available from: https://www.bdbiosciences.com/content/dam/bdb/products/global/reagents/flow-cytometryreagents/clinical-diagnostics/multicolor-cocktails-and-kits-ivdce-ivds/662967_base/pdf/23-19817.pdf Search in Google Scholar

17 Demaret J, Varlet P, Trauet J, Beauvais D, Grossemy A, Hégo F, et al. Monitoring CAR T-cells using flow cytometry. Cytometry B Clin Cytom. 2021 Mar;100(2):218-24. DOI: 10.1002/cyto.b.21941 Search in Google Scholar

18 Peinelt A, Bremm M, Kreyenberg H, Cappel C, Banisharif-Dehkordi J, Erben S, et al. Monitoring of Circulating CAR T Cells: Validation of a Flow Cytometric Assay, Cellular Kinetics, and Phenotype Analysis Following Tisagenlecleucel. Front Immunol. 2022;13:830773. DOI: 10.3389/fimmu.2022.830773 Search in Google Scholar

19 Blache U, Weiss R, Boldt A, Kapinsky M, Blaudszun AR, Quaiser A, et al. Advanced Flow Cytometry Assays for Immune Monitoring of CAR T Cell Applications. Front Immunol [Internet]. 2021 [cited 2023 Apr 19];12. Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2021.658314 DOI: 10.3389/fimmu.2021.658314 Search in Google Scholar

20 Kochenderfer JN, Somerville RPT, Lu T, Yang JC, Sherry RM, Feldman SA, et al. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. Mol Ther J Am Soc Gene Ther. 2017 Oct 4;25(10):2245-53. DOI: 10.1016/j.ymthe.2017.07.004 Search in Google Scholar

21 Liu Q, Sun Z, Chen L. Memory T cells: strategies for optimizing tumor immunotherapy. Protein Cell. 2020 Aug;11(8):549-64. DOI: 10.1007/s13238-020-00707-9 Search in Google Scholar

22 Busch DH, Fräßle SP, Sommermeyer D, Buchholz VR, Riddell SR. Role of memory T cell subsets for adoptive immunotherapy. Semin Immunol. 2016 Feb;28(1):28-34. DOI: 10.1016/j. smim.2016.02.001 Search in Google Scholar

23 Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018 Oct;24(10):1499-1503. DOI: 10.1038/s41591-018-0201-9 Search in Google Scholar

24 Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med. 2014 Oct 16;371(16):1507-17. DOI: 10.1056/NEJMoa1407222 Search in Google Scholar